Advertisement

ESMO 2022: Adjuvant Atezolizumab for Patients With RCC at Increased Risk of Recurrence After Resection
Posted: 09/21/2022 | By: Sarah Campen, PharmD

The phase III IMmotion010 trial evaluated atezolizumab monotherapy vs placebo as adjuvant therapy in patients with renal cell carcinoma (RCC) who were at increased risk of recurrence after resection. Data from the trial was presented by Bex et al at the European Society for Medical Oncology (ESMO) Congress 2022 ( Abstract LBA6).

Question 1 of 5

The median investigator-assessed disease-free survival in the atezolizumab vs placebo treatment groups was:

Choose 1

A
52.4 months vs 41.2 months (P = .045)
B
57.2 months vs 49.5 months (P = .495)
C
59.3 months vs 55.7 months (P = .724)
D
56.8 months vs 47.2 months (P = .097)

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage